Rafarma Pharmaceuticals, Inc. (RAFA) Operational Subsidiary

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Rafarma Pharmaceuticals, Inc. (RAFA) Operational Subsidiary Introduces New Board of Directors

TERBUNY, RUSSIA--(Marketwired - Jul 17, 2013) - The pharmaceutical plant operations of Rafarma Pharmaceuticals, Inc. ( OTC : RAFA ) are run by its operational subsidiary, "ZAO Rafarma." Day-to-day production activities, as well as operational and business expansion, are led by a well-qualified team of pharmaceutical and business professionals. A new Board of Directors for ZAO Rafarma was recently elected and includes the following industry veterans:

Nadezhda Brusnitsina, Chairman of the Board - Former director of the MBA program for the Russian Academy of National Economy and State Service, under the President of the Russian Federation, where she was also a Professor in the Department of Project Management. Ms. Brusnitsina has a PhD in Economics and over 13 years' experience in management.

Irina Shashkova, First Deputy to Director-General - With more than 30 years experience in various pharmaceutical enterprises, Ms. Shashkova provides a broad range of skills in the industry. She was awarded a certificate of excellence by the Ministry of Health of Russian Federation for her work in advancing pharmaceutical initiatives in Russia.

Andrey Sinitsin, M.D. - Dr. Sinitsin is a medical professional with over 10 years experience in marketing and sales of pharmaceutical products. Mr. Sinitsin has been a key contributor in growing Rafarma, particularly in the procurement of production contracts for the company.

Mikhail Nazarychev - Mr. Nazarychev's experience and skill set are in investment and commercial banking. Mr. Nazarychev obtained his educational degrees at the Russian Federation Finance Academy where he majored in banking and finance. Mr. Nazarychev has played a key role in the financing of the company's growth and expansion.

Tatiana Leontieva, J.D. - A graduate of Moscow University in Social law, Ms. Leontieva is a seasoned corporate professional who also has held important government positions for the Russian Federation. Ms. Leontieva was part of the team that initiated and founded ZAO Rafarma. She also holds board positions, including a chairmanship, with industry-related companies.

Hartmut Gerlof - Vice President of Textima, Germany . Mr. Gerlof brings to Rafarma a lengthy history of corporate management of large companies within the industry. Mr. Gerlof's experience allows him to facilitate relations with the German Science and Manufacturing communities for the expansion of Rafarma's revenue opportunities in Germany.

Professor Dr. Hartwig Steckel - Dr. Steckel is a licensed pharmacist as well as the Director of the Department of Pharmaceutics and Biopharmaceutics (Institute of Pharmacy) at Christian Albrecht University in Kiel, Germany. Dr. Steckel is also a member of the International Association for Pharmaceutical Technology (APV), the American Association for Pharmaceutical Scientists (AAPS) and the German Pharmaceutical Society (DPhG).

CEO Dave Anderson stated: "We welcome these new members and look forward to working closely with such a diverse and experienced board."

About Rafarma Pharmaceuticals, Inc.

Operating from a new 270,000 square-foot state-of-the-art manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation. For the last three years, the Russian Government has been highly focused on bolstering the development of nation's domestic pharmaceutical industry. Rafarma Pharmaceuticals' mission is to work with the auspices of aggressive federal initiatives to fast-track the modernization of Russia's pharmaceutical industry.

For more information on Rafarma Pharmaceuticals, visit: http://RAFA.QualityStocks.net

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.

RELATED LINKS Website: www.Rafarma.com Facebook: www.facebook.com/Rafarmainfo Twitter: www.twitter.com/Rafarmainfo Videos: www.video.QualityStocks.net

Company Dave Anderson Rafarma Pharmaceuticals, Inc. 801.210.7135 Info@Rafarma.com Investor Relations QualityStocks Scottsdale, Arizona www.QualityStocks.com 480.374.1336 Office Editor@QualityStocks.net

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 89

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 57

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
AI Echo Study Sharpens a Difficult HFpEF Diagnosis

Updated Category News Views 71

A single echo clip may be doing more useful work than plenty of flashy healthcare AI demos. The November 2026 Journal of Cardiac Failure focus issue puts a hard number on that possibility: pairing an AI read of a routine echocardiogram clip with the H?FPEF clinical score identified 78% of patients with hemodynamically confirmed HFpEF, versus 48% with the score alone. That...

Continue Reading
Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 291

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 93

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 105

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading
Midea's Cooling Systems Take Center Stage at DCW ME

Updated Category News Views 64

AI Surge Demands Cooler Solutions Alright, who'd guess that data centers would feel the heat—literally—like a welder's furnace in Abu Dhabi? As AI demand burns hotter across the Middle East, data centers are sweating it out against 50°C-plus temperatures. We're talking about some serious pressure on traditional cooling methods that just can’t cut it anymore....

Continue Reading
Knotch Bets Brands Need Answers, Not More Web Pages

Updated Category News Views 147

Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 25

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 76

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading

Top 5 Most Recently Viewed Articles

Surge in Gold Prices Reflects Political and Economic Tensions

Updated Category News Views 283

Gold Prices Reach New Heights Amid Political Turmoil Gold prices have reached unprecedented levels recently, reflecting a surge in safe-haven demand driven by rising political uncertainties in key regions like the U.S. and Japan. As concerns about potential economic instability grow, this precious metal has emerged as a popular choice for investors looking to protect...

Continue Reading
BlackSky Secures Navy Contract to Enhance Satellite Imaging

Updated Category News Views 222

Alright, here’s the scoop: BlackSky Technology Inc. just bagged a major contract with the U.S. Navy, and it’s all about beefing up their Gen-3 imaging satellites. Now, why does this matter? This initiative is a piece of the broader Project Overmatch—a military strategy designed to supercharge the Joint All Domain Command and Control (JADC2) mission. What’s at...

Continue Reading
Discover the Innovative FINGER GRIP for Enhanced Sports Performance

Updated Category News Views 217

Enhancing Sports with the Innovative FINGER GRIP In the dynamic world of sports, having the right equipment can make all the difference. An inventive mind from Pittsburgh has introduced an innovative product, the FINGER GRIP, aimed at elevating performance in games like pickleball and tennis. This new grip is revolutionizing how athletes interact with their paddles and...

Continue Reading
Updated Voting Shares of AB Volvo: Significant Changes

Updated Category News Views 215

Changes in AB Volvo's Voting Shares AB Volvo has recently undergone an important transformation affecting its voting shares. The conversion of 175,000 Series A shares into Series B shares is a key development for the company. This conversion stems from a provision accepted at the 2011 Annual General Meeting, allowing Series A shareholders to switch their shares to Series...

Continue Reading
Warner Bros. Discovery's Q4: Strong Revenue Growth & Future Plans

Updated Category News Views 324

Warner Bros. Discovery Reports Impressive Q4 Results In a recent financial assessment, Warner Bros. Discovery, Inc (NASDAQ: WBD) unveiled its latest quarterly performance, showcasing a fiscal fourth-quarter revenue of $10.03 billion. Although this represented a slight 1% ex-FX decline compared to the previous year, it was just shy of analysts' expectations of $10.19...

Continue Reading